New MS drug Gilenya Approved for First-Line Therapy

Posted: 01.26.2011

Kottil Rammohan, M.D., professor of neurology and director of the Multiple Sclerosis Center at the University of Miami Miller School of Medicine, discusses Gilenya (fingolimod), a new drug approved by the FDA as a first-line therapy for multiple sclerosis. Dr. Rammohan addresses the efficacy of the drug and whether cost will limit the usage to second-line therapy.